Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab, enhancing understanding of its immune modulation effects [1][4]. Group 1: Study Findings - The study identified gene expression changes starting three months after intranasal dosing of foralumab, with key findings related to antigen presentation and interferon responses [2]. - Single-cell RNA sequencing revealed gene expression changes associated with nasal foralumab, correlating with reduced microglial brain inflammation as measured by PET scans [3]. Group 2: Clinical Implications - The findings indicate potential for nasal foralumab in modulating critical immune pathways, paving the way for personalized treatment strategies for MS [4]. - Clinical stabilization and microglial PET findings support the biological effects of nasal foralumab, establishing a framework for monitoring treatment efficacy in future trials [4]. Group 3: Product Information - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally, with positive outcomes observed in 10 patients with na-SPMS [5]. - The FDA has allowed enrollment of an additional 20 patients in the Expanded Access Program, indicating ongoing interest and potential for further clinical exploration [5]. Group 4: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, with a lead candidate of intranasal foralumab showing a favorable safety profile [9]. - The company's approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods, with several patents pending for its technology [9].

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation. This advan ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled "Immune mechanisms and shared immune targets in neurodegenerative diseases" was published in Nature Reviews Neurology, highlighting the therapeutic potential of intranasal ...

Core Article Summary - The article highlights the therapeutic potential of intranasal Foralumab, a fully human anti-CD3 monoclonal antibody, for treating neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer’s disease, ALS, and Parkinson’s disease [1][8] - Foralumab works by dampening microglial activation, a key driver of disease in these neurological conditions, and has shown no apparent side effects with easy administration [1] - The review article emphasizes the role of the immune system in neurodegenerative diseases, with microglia being a common therapeutic target [4][9] Clinical Development and Trials - Foralumab is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis (NCT06292923), with 10 patients already dosed in an Expanded Access Program showing improvement or stability within 6 months [5] - The FDA has allowed an additional 20 patients to be enrolled in the Expanded Access Program [5] - The Phase 2 trial for non-active SPMS began screening patients in November 2023 [2] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulation therapies using alternative drug delivery technologies, such as intranasal administration [6] - The company’s lead candidate, intranasal Foralumab, is the only fully human anti-CD3 monoclonal antibody in clinical development and has demonstrated a favorable safety profile and clinical response in studies [6] - Tiziana’s technology for alternative routes of immunotherapy has been patented, with several applications pending, enabling broad pipeline applications [6] Scientific Insights - The review article discusses how microglia, monocytes, and T cells contribute to the pathogenesis of neurodegenerative diseases and their potential as shared therapeutic targets [9] - The microbiome is highlighted as an emerging therapeutic target that indirectly modulates the immune system [9] - Foralumab modulates T cell function by binding to the T cell receptor, dampening inflammation and suppressing effector features in immune cells [10] Industry Implications - Immunotherapeutic approaches targeting the adaptive and innate immune systems are being explored for the treatment of neurological diseases, with common targets and approaches across diseases [4] - The intranasal delivery of Foralumab represents a promising therapeutic avenue for patients with limited treatment options, particularly in progressive MS and other neurological diseases [1][6]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a significant milestone in its clinical development program for Alzheimer’s disease. The Company has successfully dosed the first patient with moderate Alzheimer's disease using intranasal foralumab a ...

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a significant milestone in its clinical development program for Alzheimer's disease. The Company has successfully dosed the first patient with moderate Alzheimer's disease using intranasal foralumab at ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...